Nutriband Inc. (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received approval from the U.S. Food and Drug Administration (FDA) for a Type C meeting regarding its AVERSA™ abuse-deterrent technology for fentanyl patches. The scheduled meeting with the FDA's Division of Anesthesiology, Addiction Medicine, and Pain Medicine on September 18 will focus on Chemistry, Manufacturing, and Controls (CMC) plans covering the complete development and commercialization timeline for the product.
This regulatory milestone enables Nutriband to pursue the 505(b)(2) pathway for New Drug Application (NDA) approval, which allows the company to leverage existing safety data for fentanyl while concentrating regulatory review on the novel abuse-deterrent components of its AVERSA™ technology. The development pathway addresses the entire process from Investigational New Drug (IND) submission through to potential market approval, providing a clear regulatory framework for bringing the product to market.
The AVERSA™ technology represents a significant advancement in transdermal drug delivery systems designed to prevent abuse, misuse, diversion, and accidental exposure to drugs with abuse potential. This technology can be incorporated into any transdermal patch, offering broad applications beyond fentanyl for various medications with abuse risks. The FDA's engagement signals recognition of the product's potential to address critical unmet medical needs in opioid safety and abuse prevention.
For more information about Nutriband's technology and development programs, visit https://www.Nutriband.com. Additional news and updates relating to NTRB are available through the company's newsroom at https://ibn.fm/NTRB.
The development of abuse-deterrent formulations has become increasingly important in addressing the ongoing opioid crisis, with regulatory agencies prioritizing technologies that can reduce the potential for misuse while maintaining therapeutic efficacy for legitimate pain management. Nutriband's progress through the FDA engagement process demonstrates the growing emphasis on innovative solutions to combat prescription drug abuse, potentially setting new standards for transdermal drug safety and influencing future regulatory requirements for abuse-deterrent technologies across the pharmaceutical industry.
